Study:
Randomized Phase III Crossover Trial of Chemotherapy (Doxorubicin/Cisplatin/Paclitaxel and G-CSF) Versus Hormonal Therapy (Tamoxifen/Megestrol Acetate) in Patients With Stage III & IV or Recurrent Endometrial Cancer
Rationale:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Estrogen can stimulate the growth of tumor cells. Hormone
therapy using tamoxifen and megestrol may fight endometrial cancer by blocking the
absorption of estrogen. It is not yet known whether chemotherapy is more effective than
hormone therapy in treating endometrial cancer.
Purpose:
Randomized phase III trial to compare the effectiveness of combination chemotherapy
with that of hormone therapy in treating patients who have recurrent, stage III, or stage IV
endometrial cancer.
Study Status: Terminated
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Endometrial Cancer |
Biological: filgrastim
Drug: cisplatin
Drug: doxorubicin hydrochloride
Drug: megestrol acetate
Drug: paclitaxel
Drug: tamoxifen citrate |
Phase 3 |
Verified by
Gynecologic Oncology Group
June, 2007
Sponsored by: Gynecologic Oncology Group
Information provided by: Gynecologic Oncology Group
ClinicalTrials.gov identifier: NCT00016341
Study Type: Interventional
Study Design: Allocation: Randomized, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Jeffrey D. Bloss, MD., Study Chair